HuR/HIF – SIRT1 Signaling Axis in Liver Transplant Rejuvenation
HuR/HIF – SIRT1 Signaling Axis in Liver Transplant Rejuvenation
批准号:
10597038
负责人:
Jerzy W Kupiec-Weglinski
金额:
$46.12万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
未结题
起止时间:
2003-04-01 至 2026-03-31
关键词:
AcuteAnti-Inflammatory AgentsAntigensBiological MarkersBiopsy SpecimenChronicClinicalCoculture TechniquesCytoprotectionDNA-Binding ProteinsDeacetylaseDeacetylationDepressed moodEnzymesFeedbackGenetic TranscriptionGoalsHIF1A geneHepaticHepatic TissueHepatocyteHomeostasisHumanHydrogen PeroxideHypersensitivityHypoxiaHypoxia Inducible FactorITGAM geneImmuneInflammationInflammatory ResponseInterventionIschemiaLaboratoriesLearningLicensingLifeLinkLiverLiver neoplasmsMacrophageMacrophage ActivationMediatingMediatorMessenger RNAMusMyelogenousNatural ImmunityOrganOrgan DonorOrgan TransplantationOutcomeOxidative StressPathway interactionsPatientsPerfusionPredispositionProteinsRecoveryRegulationRejuvenationReperfusion InjuryReperfusion TherapyRepressionResistanceResveratrolSignal TransductionSolidSterilityStressSystemTemperatureTestingTherapeuticTissuesTransgenic ModelTranslatingTransplant RecipientsTransplantationbench to bedsidebiological adaptation to stresscell growth regulationcell injuryclinically relevantcold stressconditioningcytokinedelayed graft functionend stage liver diseaseexperienceexperimental studyfunctional improvementimprovedin vitro Modelinhibitorinnovationliver biopsyliver functionliver inflammationliver injuryliver ischemialiver transplantationmouse modelnatural hypothermianovelpharmacologicpreconditioningpreservationprogramsreconstitutionresponseretransplantationstandard of caresuccesssynergismtransplant model
中文摘要
摘要
英文摘要
ABSTRACT
Orthotopic liver transplantation (OLT) is the gold standard of care in patients with end-stage liver disease and
those with tumors of hepatic origin. However, the scarcity of donor organs prompted the use of extended criteria
“marginal” livers, which are particularly susceptible to ischemia-reperfusion injury (IRI), which predispose to
acute/chronic rejection, and may require re-transplantation. We have introduced the concept of organ
“rejuvenation”, i.e., conversion of the donor liver from the state of IRI-hypersensitivity to the homeostatic state of
IRI-resistance. We have also proposed that SIRT1 deacetylase serves as a rheostat linking IR-stress with liver
rejuvenation in both, mouse and human OLT. We have recently identified new regulators of hepatic resistance
against warm vs. cold ischemia stress responses, i.e., Human Antigen R (HuR) and Hypoxia-Inducible Factor
(HIF-1α). We have also discovered Ikaros (IKZF1), acts as a macrophage activation marker and exacerbates
liver IRI. Importantly, we also found that preserved hepatocellular function/improved clinical outcomes in human
OLT patients were associated with increased HuR/HIF-1α but depressed Ikaros levels in the liver biopsy
samples. We hypothesize that crosstalk between hepatocyte HuR / HIF-1α and macrophage Ikaros provides a
new means to regulate the adaptation of donor livers to IR-stress and reperfusion-mediated hepatic damage.
Specific Aim 1: Determine mechanisms of hepatocyte HuR / HIF-1α crosstalk with SIRT1 in IRI-OLT.
Hypothesis: Hepatocyte SIRT1 activation, controlled by distinct hypoxia/reoxygenation (H/R) requirements for
HuR (warm H/R) vs. HIF-1α (cold H/R), provide new means to regulate adaptation of donor livers to IR-stress.
1.1: SIRT1 function is dependent on HuR signaling for anti-inflammatory responses in oxidative stress. 1.2:
HuR/HIF-1α signaling in a mouse model of hepatic ischemia is temperature stress-dependent. 1.3: HIF-1α
controls cold-induced IRI-OLT. 1.4: HuR controls warm-induced IRI-OLT.
Specific Aim 2: Delineate mechanisms of macrophage Ikaros crosstalk with SIRT1 in IRI-OLT.
Hypothesis: Macrophage Ikaros signaling exacerbates IRI-OLT by repressing SIRT1 transcription and M2
macrophage polarization. 2.1: Ikaros-SIRT1 myeloid axis influences hepatic HuR/HIF1α hypoxia sensing circuit
in IRI-OLT. 2.2: Macrophage Ikaros signaling depends on SIRT1 transcription for M2 polarization.
Specific Aim 3: Define mechanism of human liver rejuvenation under hypothermic machine preservation.
Hypothesis: Manipulation of HIF-1α / SIRT1 axis during ex-vivo HMP improves hepatocellular function to
rejuvenate human livers declined for transplantation due to preexisting poor quality. 3.1: Pharmacological
stabilizer of HIF-1α protein synergizes with SIRT1 to improve human liver function. 3.2: Preconditioning with
PHD-inhibitor, which activates/stabilizes HIF-1α, synergizes with enhanced SIRT1 signaling to ameliorate
inflammation, promote cytoprotection, and rejuvenate human livers. These experiments are of high relevance to
refine donor liver donation (DBD and DCD) as well as to improve quality/size of the current organ supply.
期刊论文(54)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/hep.31831
发表时间:
2021-09
期刊:
HEPATOLOGY
影响因子:
13.5
作者:
[Sheng, Mingwei, Lin, Yuanbang, Xu, Dongwei, Tian, Yizhu, Zhan, Yongqiang, Li, Changyong, Farmer, Douglas G., Kupiec-Weglinski, Jerzy W., Ke, Bibo]
通讯作者:
Ke, Bibo
DOI:
10.1002/hep.31093
发表时间:
2020-09
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
作者:
[Dery KJ, Nakamura K, Kadono K, Hirao H, Kageyama S, Ito T, Kojima H, Kaldas FM, Busuttil RW, Kupiec-Weglinski JW]
通讯作者:
Kupiec-Weglinski JW
SIRT1 Regulates Hepatocyte Programmed Cell Death via GSDME - IL18 Axis in Human and Mouse Liver Transplantation.
SIRT1 在人和小鼠肝脏移植中通过 GSDME - IL18 轴调节肝细胞程序性细胞死亡。
DOI:
10.21203/rs.3.rs-2986981/v1
发表时间:
2023
期刊:
Research square
影响因子:
--
作者:
[Kadono,Kentaro, Kojima,Hidenobu, Yao,Siyuan, Kageyama,Shoichi, Nakamura,Kojiro, Hirao,Hirofumi, Ito,Takahiro, Dery,Kenneth, Farmer,Douglas, Kaldas,Fady, Li,Xiaoling, Kupiec-Weglinski,Jerzy]
通讯作者:
Kupiec-Weglinski,Jerzy
DOI:
10.1111/j.1600-6143.2012.04021.x
发表时间:
2012-07
期刊:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子:
--
作者:
[Shen XD, Ke B, Ji H, Gao F, Freitas MC, Chang WW, Lee C, Zhai Y, Busuttil RW, Kupiec-Weglinski JW]
通讯作者:
Kupiec-Weglinski JW
DOI:
10.1016/j.jhep.2021.11.026
发表时间:
2022-04
期刊:
JOURNAL OF HEPATOLOGY
影响因子:
25.7
作者:
[Kadono, Kentaro, Kageyama, Shoichi, Nakamura, Kojiro, Hirao, Hirofumi, Ito, Takahiro, Kojima, Hidenobu, Dery, Kenneth J., Li, Xiaoling, Kupiec-Weglinski, Jerzy W.]
通讯作者:
Kupiec-Weglinski, Jerzy W.
共 29 条
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10101174
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10685284
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10472636
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10268216
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immune Interface in Liver Ischemia-Reperfusion Injury
-
批准号:9975698
-
项目类别:
-
资助金额:$38.23万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9359428
-
项目类别:
-
资助金额:$168.58万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10328210
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10622462
-
项目类别:
-
资助金额:$54.09万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:9975689
-
项目类别:
-
资助金额:$12.17万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9975685
-
项目类别:
-
资助金额:$167.45万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9750602
-
项目类别:
-
资助金额:$168.08万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10622453
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10622451
-
项目类别:
-
资助金额:$194.91万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10328213
-
项目类别:
-
资助金额:$53.42万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10328209
-
项目类别:
-
资助金额:$194.13万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9198218
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9005628
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:9029320
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:8895119
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HO1 ANDTLR4 IN LIVER ISCHEMIA/REPERFUSION INJURY IN TRANSPLANT RECIPIENTS
-
批准号:7808751
-
项目类别:
-
资助金额:$61.6万
-
财政年份:2009
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
海外基金